- Home
- PRKS vs NVCR Comparison
PRKS vs NVCR Comparison
Compare PRKS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRKS | NVCR |
|---|---|---|
| Founded | 1959 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRKS | NVCR |
|---|---|---|
| Price | $45.22 | $18.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $47.50 | $28.08 |
| AVG Volume (30 Days) | 667.4K | ★ 1.7M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $1,263,324,000.00 | $655,353,000.00 |
| Revenue This Year | $3.45 | $7.72 |
| Revenue Next Year | $3.08 | $6.74 |
| P/E Ratio | $75.05 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $28.77 | $9.82 |
| 52 Week High | $56.95 | $21.45 |
Technical Indicators
Market Signals| Indicator | PRKS | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 57.67 |
| Support Level | $44.00 | $14.84 |
| Resistance Level | $49.08 | $18.37 |
| Average True Range (ATR) | 1.94 | 0.73 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 35.71 | 90.51 |
Price Performance
Historical ComparisonAbout PRKS United Parks & Resorts Inc.
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.